Market Research Report : Indian Anti-infective Pharma market 2012

2,728 views

Published on

For the complete report, get in touch with us at : info@netscribes.com

Anti-infective pharmaceuticals market in India is the largest contributor to domestic pharmaceutical sales, contributing around 18%. Since India has a huge patient pool, the Indian market is characterized by a huge demand for anti-infective drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, increasing number of vaccine approvals, increase in health insurances and introduction of newer and better drugs is helping the market to grow. The Indian Government, on its part, has introduced some control programmes, undertaken various Private Partnership Projects (PPP) and has taken initiatives to reduce drug prices. The market is expected to exhibit steady growth over the next few years.

The report begins with the introduction section which offers a brief classification of the anti infectives market. It then moves to the market overview section which provides an insight into the global market and then moves on to the Indian market, highlighting the market size and growth.

An analysis of the drivers explains the factors for growth of the industry including increasing patient population, increasing vaccine approvals, increase in health insurances and introduction of newer and better drugs. The key challenges include pricing pressure and logistic problems in the vaccine market.

The government initiatives section gives a brief description of the different control programmes undertaken by the Government. It also analyses the efforts to reduce drug prices, changes in the customs duty structure and the various PPP projects undertaken by the Government.

A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals for anti infective drugs.

The competition section gives overview of pharmaceutical companies in the country operating in the anti diabetic pharmaceutical and insulin segments. Thereafter, the report highlights the features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. Porters Five Forces Analysis has been incorporated for a brief but effective understanding of the market scenario. It also incorporates the recent developments in the Anti Infective Pharmaceutical industry.

The strategic recommendations section focuses on some effective strategic decisions which can be taken up by companies to increase their market shares. Foray into the production of adult vaccines and improvement in the logistics of the vaccine market will help the companies increase their customer base.

Published in: Business, News & Politics
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
2,728
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
74
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Market Research Report : Indian Anti-infective Pharma market 2012

  1. 1. Anti‐Infective Pharmaceuticals Market ‐ IndiaApril 2012
  2. 2. Executive Summary  Global anti‐infective pharmaceuticals market was valued at INR xx.x units while in India it was  valued at INR yy.y units in 20‐‐  The market is expected to grow at a CAGR of m% from 20‐‐ to 20‐‐ globally and at n% CAGR in  Market India  Anti infectives are the largest contributor to India’s domestic sales in 20‐‐, contributing around  z%  Drivers and  Drivers:  Increasing patient population LE   Challenges:  Pricing pressure Challenges M  Increase in health insurancesP  Increasing number of vaccine approvals  Logistic problems in the vaccine market Drug Regulation  and Patents  Introduction of new drugs  Phases of clinical trial S A  Approval and licensing of drugs  Patents  Highly fragmented market with large number of players Competition  Major foreign players in the market include Gilead inc, Abbott, Glaxosmithkline etc  Major domestic companies include Ranbaxy, Cipla, Dr. Reddy’s, Sun Pharmaceuticals, Panacea  Biotech, Torrent Pharmaceuticals among others  Strategic   Foray into the adult vaccine marketRecommendations  Strategic partnerships with Governmental and private bodies ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 2
  3. 3. •Introduction•Market Overview LE  •Drivers & Challenges M•Government InitiativesP S A•Market Value Chain, Regulation and  Patents•Competition•Strategic Recommendation•Appendix ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 3
  4. 4. Indian anti‐infectives market is expected to witness an  enormous growth over the coming years Indian Market – Overview  Market Size and Growth • Anti‐infectives belong to the acute segment which  INR units makes up around z% of the total pharmaceutical  200 industry x% x6   150 x5 x4 LE  Anti‐infectives are the largest contributor to domestic  x3 pharmaceuticals sales, contributing around y% x2 100 x1 P  Cephalosporins, penicillins and quinolones are key drug  classes among anti‐infectives, with a share of around z% of  50 M the country’s anti‐infectives market 0 • Presently the market has a size of INR X bn, and is  A 20‐‐ 20‐‐ 20‐‐e 20‐‐e 20‐‐e 20‐‐e expected to grow at a CAGR of x% from 20‐‐‐‐‐ • In 20‐‐ GSK’s Augmentin was the highest selling drug  with sales of INR Y bn S  Zifi, Taxim ,Monocef, Mox, Taxim‐O , Zinacef and Gerimac Top pharmaceutical segments – 20‐‐ anti‐infectives 0 2 4 6 8 10 12 14 16 18 % y1 were the other top selling drugs  CVS y2 • India has emerged as one of the leading vaccine  gastro y3 manufacturer in recent times, producing z% of the  CNS y4 global health vaccines respiratory y5  Pentaxim, Varivax and Prevenar were the top selling  diabetes y6 vaccines in 20‐‐ pain y7 oncology y8Source: ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 4
  5. 5. Drivers & Challenges – Summary LE   Drivers MP Challenges Increasing patient population Increasing number of vaccine  approvals S A Pricing pressure Logistic problems in the vaccine  market Increase in health insurances Introduction of new drugs ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 5
  6. 6. Government Initiatives – Summary Changes in tax structure Control programmes  Government  Initiatives LE   PPP Projects Reduction in drug prices MP S A ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 6
  7. 7. Pharmaceutical value chains involve the entire process  from drug discovery to drug marketing A pharmaceutical value chain is a chain of activities which are involved in producing drugs, starting with raw  materials and ending with the delivered product Sales  Drug  Drug  Manufacturing Distribution  and  Discovery Development Marketing   Drug development  Distribution of a  Pharmaceutical  LE Drug discovery  is the process of  Drug  manufactured drug  marketing,  involves the  bringing a new  manufacturing are  involves the  sometimes called  P identification,  drug to the market  the systems  process by which  medico marketing,  synthesis and  once a lead  required for the  the drug is  is the process of  M screening of  compound has  quality control  supplied to the  advertising or  A chemicals for  been identified  covering the  stockists,  otherwise  therapeutic  through the  manufacture and  substockists,  S promoting the sale  efficacy process of drug  testing of drugs hospitals and retail  of drugs  discovery pharmacy shopsSource:  ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 7
  8. 8. Public: Domestic Company – A Company (1/3) Company Information Offices and Centres – India  X Road Corporate Address Bangalore Tel No. +91 xx xxxxx xxxxx Fax No. Website +91 xx xxxxx xxxxx www.ppp.com LE   P Year of Incorporation 19‐‐ M Ticker Symbol xxxxxx A Stock Exchange NNN Products and Services Category Products/Services S City A   Head Office CVD, CNS, respiratory, dermatology,  Key People Pharmaceutical orthopedics, nutritional, urology, anti‐ infectives Name Designation Infectious diseases, metabolic diseases,  Person M Founder Molecule  inflammatory/respiratory diseases, and  Person N CFO Development oncology Person O Head Person Q PresidentSource: ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 8
  9. 9. Public: Domestic Company – A Company (2/3) Financial Snapshot Key Ratios Revenue Profit Particulars  y‐o‐y change 20‐‐ 20‐‐ 20‐‐ 20‐‐ INR mn  Revenue INR mn  Profitability Ratios q r Profit / Loss10,000 p Operating Margin s Net Margin   n Profit Before Tax Margin LE 5,000 m n o p 0 Return on Equity t Return on Capital Employed P 0 ‐m Return on Working Capital 20‐‐ 20‐‐ 20‐‐ 20‐‐ Return on Assets M Financial Summary  Return on Fixed Assets Cost Ratios • The company incurred a net loss of INR xx mn in FY 20‐‐, as  compared to net profit of INR  yy mn in FY 20‐‐ • The company reported total income of  INR xx bn in FY 20‐‐,  registering an increase of yy per cent over FY 20‐‐ • The company earned an operating margin of x per cent in FY 20‐‐ a  S A Operating costs (% of Sales) Administration costs (% of  Sales) Interest costs (% of Sales) Liquidity Ratios Current Ratio decrease of y percentage points over FY 20‐‐ Cash Ratio • The company reported debt to equity ratio of x in FY 20‐‐, an  Leverage Ratios increase of y per cent over FY 20‐‐ Debt to Equity Ratio Debt to Capital Ratio Financial Summary  Interest Coverage Ratio Indicators Present Value  Efficiency Ratios Market Capitalization (INR) X units Fixed Asset Turnover Total Enterprise Value (INR) Y units Asset Turnover Current Asset Turnover EPS (INR) Z units Working Capital Turnover PE Ratio (Absolute) A Capital Employed Turnover Source: Improved Decline ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 9
  10. 10. Public: Domestic Company – A Company (3/3) Key Business Segments Key Geographic Segments m n o x y z   x x LE x x x x x y x y y y z y z y z y z y MP z 20‐‐ z 20‐‐ z 20‐‐ z 20‐‐ A 20‐‐ 20‐‐ 20‐‐ 20‐‐ Key Recent Developments Overview Description  S News • Company A is an integrated research based company that produces a wide range of generic medicines • Serves customers in over 100 countries with manufacturing facilities in several countries Anti Infectives • Anti infective drugs and injectibles include Product 1 and Product 2  Pharmaceuticals • Is making consistent effort for continual improvement in rural areas with respect to accessibility of  Key Initiatives medicinesSource: ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 10
  11. 11. Thank you for the attentionThe Anti‐Diabetic Pharmaceuticals  Market – India report is part of Netscribes’ Healthcare Industry Series. For more detailed information or customized research requirements please contact:Contact Number: +91 33 4064 6215 E‐Mail: sales@netscribes.comNetscribes (India) Pvt. Ltd. is dedicated to disseminating information and providing quick insights on “hot” industries in India and other emerging markets. Track our new releases and major updates in these industries onAbout NetscribesNetscribes is a knowledge‐consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment & business research, business & corporate intelligence, content‐management services, and knowledge‐software services. At its core lies a true value proposition that draws upon a vast knowledge base. Netscribes is a one‐stop shop designed to fulfil clients’ profitability and growth objectives.Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Netscribes (India) Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction. ANTI INFECTIVE PHARMACEUTICAL MARKET IN INDIA 2012.PPT 11

×